{"title":"补充多菌种合生素对血脂异常患者血清脂质概况、肠道有益菌丰度和固缩菌与类杆菌比例的影响;一项随机、双盲、安慰剂对照临床试验","authors":"Shekoufeh Salamat , Mohammad Reza Tabandeh , Alireza Jahan-Mihan , Anahita Mansoori","doi":"10.1016/j.phanu.2023.100367","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span><span><span>Dysbiosis an imbalance of </span>gut microbiota (GM) may contribute to the development of </span>metabolic disorders<span> including dyslipidemia<span>. Synbiotics have been suggested to modulate GM composition and in turn, they may alter </span></span></span>lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on </span>serum lipid<span><span> profile, abundance of dominant gut bacteria, and also the Firmicutes to </span>Bacteroidetes (F/B) ratio in adults with dyslipidemia.</span></p></div><div><h3>Methods</h3><p><span>Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×10</span><sup>10</sup><span><span><span><span> colony forming units<span>, CFU/gram) six species of probiotic<span> microorganisms with 5-gram inulin and </span></span></span>fructooligosaccharide (FOS) in equal amounts as </span>prebiotics. Serum lipid profile, </span>fecal bacteria<span><span> abundance, dietary intake, physical activity level (PAL), and </span>anthropometric measures, were assessed at the baseline and after intervention.</span></span></p></div><div><h3>Results</h3><p>No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal <span><em>Firmicutes, Bacteroidetes, </em><em>Lactobacillus</em></span>, and <span><em>Bifidobacterium</em></span> was significantly increased in the synbiotic group (p < 0.0001, p < 0.0001, p < 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.</p></div><div><h3>Conclusions</h3><p>Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"27 ","pages":"Article 100367"},"PeriodicalIF":2.4000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of supplementation with a multi-species synbiotic on serum lipid profile, abundance of beneficial gut bacteria and firmicutes to bacteroidetes ratio in patients with dyslipidemia; a randomized, double-blind, placebo-controlled, clinical trial\",\"authors\":\"Shekoufeh Salamat , Mohammad Reza Tabandeh , Alireza Jahan-Mihan , Anahita Mansoori\",\"doi\":\"10.1016/j.phanu.2023.100367\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span><span><span><span>Dysbiosis an imbalance of </span>gut microbiota (GM) may contribute to the development of </span>metabolic disorders<span> including dyslipidemia<span>. Synbiotics have been suggested to modulate GM composition and in turn, they may alter </span></span></span>lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on </span>serum lipid<span><span> profile, abundance of dominant gut bacteria, and also the Firmicutes to </span>Bacteroidetes (F/B) ratio in adults with dyslipidemia.</span></p></div><div><h3>Methods</h3><p><span>Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×10</span><sup>10</sup><span><span><span><span> colony forming units<span>, CFU/gram) six species of probiotic<span> microorganisms with 5-gram inulin and </span></span></span>fructooligosaccharide (FOS) in equal amounts as </span>prebiotics. Serum lipid profile, </span>fecal bacteria<span><span> abundance, dietary intake, physical activity level (PAL), and </span>anthropometric measures, were assessed at the baseline and after intervention.</span></span></p></div><div><h3>Results</h3><p>No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal <span><em>Firmicutes, Bacteroidetes, </em><em>Lactobacillus</em></span>, and <span><em>Bifidobacterium</em></span> was significantly increased in the synbiotic group (p < 0.0001, p < 0.0001, p < 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.</p></div><div><h3>Conclusions</h3><p>Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.</p></div>\",\"PeriodicalId\":20049,\"journal\":{\"name\":\"PharmaNutrition\",\"volume\":\"27 \",\"pages\":\"Article 100367\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmaNutrition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213434423000397\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434423000397","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
摘要
背景:肠道菌群失调(GM)可能导致代谢紊乱,包括血脂异常。合成制剂被认为可以调节转基因成分,进而改变脂质代谢。我们的目的是评估合成菌补充剂对血脂谱、优势肠道细菌丰度以及血脂异常成人厚壁菌门与拟杆菌门(F/B)比值的影响。方法:56名患有血脂异常的成年人参加了一项随机临床试验。参与者被随机分配接受合成或安慰剂包12周。每个合成小袋含有6种益生菌微生物(总剂量为3个×1010菌落形成单位,CFU/克),其中5克菊粉和低聚果糖(FOS)等量作为益生元。在基线和干预后评估血清脂质谱、粪便细菌丰度、饮食摄入量、身体活动水平(PAL)和人体测量值。结果干预12周后,组内及组间受试者的饮食摄入、PA和人体测量指标均无显著变化。高密度脂蛋白-胆固醇(HDL-C)显著升高(p = 0.0008),而其他脂质组分无显著变化。合成菌组粪便中厚壁菌门、拟杆菌门、乳酸杆菌和双歧杆菌的丰度显著增加(p <0.0001, p <0.0001, p <0.0001, p = 0.032)。然而,在研究结束时,补充12周的合成菌没有影响F/B比(p = 0.43)。结论补充多菌种合成菌12周可改善血脂异常患者的HDL-C水平,提高有益肠道菌群的丰度。
The effect of supplementation with a multi-species synbiotic on serum lipid profile, abundance of beneficial gut bacteria and firmicutes to bacteroidetes ratio in patients with dyslipidemia; a randomized, double-blind, placebo-controlled, clinical trial
Background
Dysbiosis an imbalance of gut microbiota (GM) may contribute to the development of metabolic disorders including dyslipidemia. Synbiotics have been suggested to modulate GM composition and in turn, they may alter lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on serum lipid profile, abundance of dominant gut bacteria, and also the Firmicutes to Bacteroidetes (F/B) ratio in adults with dyslipidemia.
Methods
Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×1010 colony forming units, CFU/gram) six species of probiotic microorganisms with 5-gram inulin and fructooligosaccharide (FOS) in equal amounts as prebiotics. Serum lipid profile, fecal bacteria abundance, dietary intake, physical activity level (PAL), and anthropometric measures, were assessed at the baseline and after intervention.
Results
No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal Firmicutes, Bacteroidetes, Lactobacillus, and Bifidobacterium was significantly increased in the synbiotic group (p < 0.0001, p < 0.0001, p < 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.
Conclusions
Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.